Nucl Med Mol Imaging.  2013 Dec;47(4):249-256.

18F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase

Affiliations
  • 1Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jsryu2@amc.seoul.kr
  • 2Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • 3Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • 4Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Abstract

PURPOSE
Primary systemic anaplastic large cell lymphoma (ALCL) is divided into two entities according to the expression of anaplastic lymphoma kinase (ALK). We investigated 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) findings in primary systemic ALCL according to ALK expression.
METHODS
Thirty-seven patients who had baseline PET before CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone)-based chemotherapy were enrolled. Among them, patients who underwent interim and/or post-therapy PET were further investigated for the treatment response and survival analysis. Baseline PET was analyzed visually and semi-quantitatively using peakSUV, and interim and post-therapy PETs were visually analyzed.
RESULTS
All cases were 18F-FDG-avid on baseline PET. The peakSUV of ALK-positive ALCL (n=16, 18.7+/-10.5) was higher than that of ALK-negative ALCL (n=21, 10.0+/-4.9) (P=0.006). In ALK-negative ALCL, complete response (CR) rate in negative-interim PET was higher than positive-interim PET (100 % vs 37.5 %, P=0.02); however, there was no such difference in ALK-positive ALCL (100 % vs 75 %, P=0.19). The 3-year progression-free survival (PFS) was not significantly different between ALK-positive and ALK-negative ALCL (72.7 % vs 47.6 %, P=0.34). In ALK-negative ALCL, negative interim and post-therapy PET patients had better 3-year PFS than positive interim (83.3 % vs 25.0 %, P=0.06) and post-therapy PET patients (70.0 % vs 20.0 %, P=0.04). In contrast, ALK-positive ALCL had no such differences between PFS and PET results.
CONCLUSIONS
On baseline PET, all cases showed 18F-FDG-avidity, and ALK expression was related to higher 18F-FDG uptake. ALK-positive patients tend to have better PFS than ALK-negative patients. Negative-interim PET was a good indicator of CR, and interim or post-therapy PET was helpful for predicting the prognosis only in the ALK-negative group.

Keyword

Primary systemic anaplastic large cell lymphoma; Anaplastic lymphoma kinase; 18F-FDG PET

MeSH Terms

Disease-Free Survival
Doxorubicin
Drug Therapy
Fluorodeoxyglucose F18*
Humans
Lymphoma*
Lymphoma, Large-Cell, Anaplastic*
Phosphotransferases*
Positron-Emission Tomography
Prognosis
Vincristine
Doxorubicin
Fluorodeoxyglucose F18
Phosphotransferases
Vincristine
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr